The Surge is a bioengineered adrenal augmentation developed by Lazarus Pharmaceuticals that replaces or supplements the natural adrenal gland with a synthetic tissue graft capable of producing a precisely calibrated chemical cascade on demand. Unlike crude stimulant injectors or external epinephrine delivery systems, the Phantom Graft is a living implant — vascularized, integrated into the endocrine system, and capable of producing not just adrenaline but a proprietary Lazarus-formulated cocktail that includes synthetic cortisol analogues, a selective norepinephrine amplifier, and a compound Lazarus designates LP-7 that temporarily suppresses pain signal transmission at the spinal level without affecting motor function. The graft is surgically positioned adjacent to the native adrenal tissue or in a prepared retroperitoneal space in subjects who have had the native gland removed.

The activation experience is described by users as a clean, controlled version of what natural adrenaline provides — the heightened perception, elevated strength output, and narrowed attentional focus of a fight-or-flight response, but without the shaking hands, tunnel vision failures, or post-surge crash that characterizes natural adrenaline dumps. The LP-7 component in particular produces a combat effectiveness window that operators describe as 'paying the bill later' — pain is not absent, but it is deferred, queued for delivery after the chemical window closes. Users who push through serious injuries during a Surge activation sometimes don't realize the extent of the damage until the graft cycles down, at which point the deferred pain signal arrives in full.

Lazarus Pharmaceuticals designed the Phantom Graft with a deliberate dependency architecture — the synthetic graft gradually suppresses the body's native adrenal response over 18–24 months of use, making the user increasingly reliant on the implant for any high-stress physiological response. Lazarus frames this as 'integration maturity' and offers a subscription-based proprietary maintenance compound that sustains graft viability. Users who cannot afford or access the maintenance compound experience graft degradation and, eventually, adrenal insufficiency — a chronic and potentially life-threatening condition. This has made Lazarus's maintenance subscription a point of significant controversy and the subject of ongoing regulatory disputes across GLMZ's corporate governance bodies.